Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9058 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.9058 |
High Similarity |
NPD1613 |
Approved |
0.8841 |
High Similarity |
NPD3027 |
Phase 3 |
0.8768 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8725 |
High Similarity |
NPD1653 |
Approved |
0.8696 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8447 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.8385 |
Intermediate Similarity |
NPD7054 |
Approved |
0.8333 |
Intermediate Similarity |
NPD7472 |
Approved |
0.8323 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8311 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8261 |
Intermediate Similarity |
NPD1091 |
Approved |
0.8239 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8228 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.821 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8176 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8171 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.8141 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8141 |
Intermediate Similarity |
NPD37 |
Approved |
0.8129 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8125 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8125 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8121 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.8101 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8101 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8101 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8072 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8072 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.805 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7987 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7975 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7931 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7917 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7914 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7904 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7842 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7793 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7762 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7755 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.775 |
Intermediate Similarity |
NPD2801 |
Approved |
0.775 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7746 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7725 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7725 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7712 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD7240 |
Approved |
0.764 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7639 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7639 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7607 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7593 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7569 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7564 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7546 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7535 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7533 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.753 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7484 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7482 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7464 |
Intermediate Similarity |
NPD228 |
Approved |
0.7453 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7429 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7429 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7429 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7425 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7421 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7417 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7417 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7405 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.74 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7386 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7386 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7384 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7376 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7375 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7368 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7355 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7353 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7348 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7317 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7317 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7314 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7303 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7296 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7296 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7294 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7286 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7283 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7279 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.726 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7254 |
Intermediate Similarity |
NPD6671 |
Approved |
0.725 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.725 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7244 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7244 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7239 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7226 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7226 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7226 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7212 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7212 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7194 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7194 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7179 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7179 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7178 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7178 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7174 |
Intermediate Similarity |
NPD290 |
Approved |
0.7171 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.717 |
Intermediate Similarity |
NPD6190 |
Approved |
0.717 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7169 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7169 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.716 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7159 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7159 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7159 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7152 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7134 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7134 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7123 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7123 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7115 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7107 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7107 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7107 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7107 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7105 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7102 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7102 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7095 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7051 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7048 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7048 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7047 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7039 |
Intermediate Similarity |
NPD7906 |
Approved |
0.7035 |
Intermediate Similarity |
NPD27 |
Approved |
0.7035 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7032 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7024 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.702 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7017 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7007 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7007 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.6988 |
Remote Similarity |
NPD7411 |
Suspended |
0.6983 |
Remote Similarity |
NPD4663 |
Approved |
0.6982 |
Remote Similarity |
NPD4055 |
Discovery |
0.6981 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6977 |
Remote Similarity |
NPD2969 |
Approved |
0.6977 |
Remote Similarity |
NPD2970 |
Approved |
0.6975 |
Remote Similarity |
NPD1774 |
Approved |
0.6975 |
Remote Similarity |
NPD6799 |
Approved |
0.6968 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6968 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD2563 |
Approved |
0.6964 |
Remote Similarity |
NPD2560 |
Approved |
0.6962 |
Remote Similarity |
NPD2796 |
Approved |
0.6959 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6937 |
Remote Similarity |
NPD4237 |
Approved |
0.6937 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6937 |
Remote Similarity |
NPD4162 |
Approved |
0.6936 |
Remote Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.6933 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD5401 |
Approved |
0.6933
|
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |